Overview
Matterworks uses AI to analyze mass spectrometry data for metabolomics, offering a model-as-a-service platform to researchers in therapeutic research, biomanufacturing, crop science, and animal health. Its Large Spectral Model interprets complex molecular data, and Pyxis provides a turn-key solution that identifyies and quantifies metabolites from raw data in near real-time. This speeds up R&D by turning undecoded signals into actionable biological insights, helping researchers predict outcomes in areas like protein production and sustainable agriculture. The company differentiates itself by delivering end-to-end omics analysis as a service for a broad life sciences audience, focusing on accessibility, speed, and reducing the need for specialized analytics teams to accelerate life sciences R&D.
Work here?Claim your company
Simplify's take
What believers are saying
- PyxisLabs launched July 2026, expanding revenue beyond software licensing into services.
- October 2026 benchmarks showed Pyxis identified 38% of undocumented molecules, beating frontier models.
- Paul Stone joined as CFO in February 2026, strengthening financing and partnerships execution.
What critics are saying
- Competitors can replicate mass-spectrometry workflows faster than model moats mature by 2027.
- PyxisLabs needs sustained wet-lab demand; weak utilization would burn Series A capital quickly.
- If LSM-3 underperforms on real samples, customers will revert to incumbent analytical labs.
What makes Matterworks unique
- PyxisLabs pairs LC-MS services with Pyxis software, collapsing analysis into one workflow.
- LSM-3 trained on 10 billion spectra gives Matterworks proprietary biochemical interpretation depth.
- Matterworks targets metabolomics and exposome-scale chemotyping, not generic biotech AI.
Help us improve and share your feedback! Did you find this helpful?